Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/28/2026, 1:22:44 AM
Content snapshot
{ "session_id": "sess_db9a224d-3ebb-429c-8f02-b703d71ca211_task_66f1207e_recon", "round_number": 4, "agent_persona": "persona-synthesizer", "agent_backend": "scidex.core.llm.complete", "action": "synthesize", "content": "{\n \"ranked_hypotheses\": [\n {\n \"title\": \"APOE \\u03b54-driven microglial lipid handling as proximal driver in Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers\",\n \"description\": \"APOE \\u03b54-driven microglial lipid handling should produce a measurable proximal phenotype before late disease pathology. The decisive test is isogenic APOE3/APOE4 microglia co-cultured with amyloid-bearing neurons, lipidomics, and phagocytosis/degradation assays.\",\n \"target_gene\": \"RNA-\",\n \"dimension_scores\": {\n \"evidence_strength\": 0.62,\n \"novelty\": 0.72,\n \"feasibility\": 0.67,\n \"therapeutic_potential\": 0.64,\n \"mechanistic_plausibility\": 0.7,\n \"druggability\": 0.54,\n \"safety_profile\": 0.52,\n \"competitive_landscape\": 0.58,\n \"data_availability\": 0.66,\n \"reproducibility\": 0.61\n },\n \"composite_score\": 0.626,\n \"evidence_for\": [\n {\n \"claim\": \"Spatial transcriptomics identified non-neuronal dysregulation patterns in AD; the temporal ordering of non-neuronal changes relative to tau spread was identified as a key open question.\",\n \"doi\": \"10.1038/s41380-024-02651-0\",\n \"source\": \"Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"lipid droplet accumulation may be compensatory rather than causal, and bulk amyloid readouts can miss subpopulation-specific effects\",\n \"doi\": \"10.1038/s41380-024-02651-0\",\n \"source\": \"Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease\"\n }\n ]\n },\n {\n \"title\": \"Cell-state stratification is required to resolve Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers\",\n \"description\": \"The question is likely underpowered or misleading unless analyses preserve the key strata: RNA-, APOE. Averaging across these strata could convert a causal subpopulation effect into a weak association.\",\n \"target_gene\": \"APOE\",\n \"dimension_scores\": {\n \"evidence_strength\": 0.58,\n \"novelty\": 0.64,\n \"feasibility\": 0.73,\n \"therapeutic_potential\": 0.55,\n \"mechanistic_plausibility\": 0.65,\n \"druggability\": 0.45,\n \"safety_profile\": 0.62,\n \"competitive_landscape\": 0.56,\n \"data_availability\": 0.7,\n \"reproducibility\": 0.64\n },\n \"composite_score\": 0.612,\n \"evidence_for\": [\n {\n \"claim\": \"The open question explicitly depends on cell-type, region, or molecular-state resolution.\",\n \"doi\": \"10.1038/s41380-024-02651-0\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"Stratified effects may reflect sampling or annotation artifacts rather than mechanism.\",\n \"doi\": \"10.1038/s41380-024-02651-0\"\n }\n ]\n },\n {\n \"title\": \"Perturbation-first validation should precede therapeutic claims for Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers\",\n \"description\": \"The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.\",\n \"target_gene\": \"\",\n \"dimension_scores\": {\n \"evidence_strength\": 0.55,\n \"novelty\": 0.6,\n \"feasibility\": 0.76,\n \"therapeutic_potential\": 0.57,\n \"mechanistic_plausibility\": 0.63,\n \"druggability\": 0.48,\n \"safety_profile\": 0.6,\n \"competitive_landscape\": 0.55,\n \"data_availability\": 0.68,\n \"reproducibility\": 0.66\n },\n \"composite_score\": 0.608,\n \"evidence_for\": [\n {\n \"claim\": \"The proposed priority experiment is concrete: isogenic APOE3/APOE4 microglia co-cultured with amyloid-bearing neurons, lipidomics, and phagocytosis/degradation assays\",\n \"doi\": \"10.1038/s41380-024-02651-0\"\n }\n ],\n \"evidence_against\": [\n {\n \"claim\": \"Therapeutic tractability is not established by the current source evidence.\",\n \"doi\": \"10.1038/s41380-024-02651-0\"\n }\n ]\n }\n ],\n \"knowledge_edges\": [\n {\n \"source_id\": \"db9a224d-3ebb-429c-8f02-b703d71ca211\",\n \"source_type\": \"analysis\",\n \"target_id\": \"RNA-\",\n \"target_type\": \"entity\",\n \"relation\": \"debate_reconstructs_evidence_for\"\n },\n {\n \"source_id\": \"db9a224d-3ebb-429c-8f02-b703d71ca211\",\n \"source_type\": \"analysis\",\n \"target_id\": \"APOE\",\n \"target_type\": \"entity\",\n \"relation\": \"debate_reconstructs_evidence_for\"\n }\n ],\n \"synthesis_summary\": \"Consensus: Non-Neuronal Transcriptional Changes Preceding Tau Propagation as Early AD Biomarkers is a valid debate target because it is anchored to Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal cell types in Alzheimer's disease and asks a falsifiable question about APOE \\u03b54-driven microglial lipid handling. Dissent: the source evidence does not yet prove causality, and lipid droplet accumulation may be compensatory rather than causal, and bulk amyloid readouts can miss subpopulation-specific effects. The next step is isogenic APOE3/APOE4 microglia co-cultured with amyloid-bearing neurons, lipidomics, and phagocytosis/degradation assays.\"\n}", "tokens_used": "1391", "persona_id": "persona-synthesizer" }